Article Tools

Intercell Announces next Steps of Development for Pseudomonas Vaccine

Published: April 2, 2011; 08:01 · (Vindobona)

Today Intercell AG announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into a confirmatory clinical efficacy trial in ventilated ICU (Intensive Care Unit) patients.

Intercell Announces next Steps of Development for Pseudomonas Vaccine / Picture: © Intercell

The planned double blind study is powered to show a clinically meaningful and statistically significant reduction in overall mortality between the vaccine and control group and envisages enrolling about 800 subjects. The study is subject to final regulatory concurrence and its start is planned for first half of 2012. Intercell will execute the trial and the costs will be shared with…

This article includes a total of 304 words.

or Log In